The purpose of this study is to evaluate the safety and tolerability of Egalet-002 in opioid-experienced patients with moderate-to-severe chronic noncancer pain.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
281
Incidence of TEAEs during the Open-label Treatment Period, including those leading to treatment withdrawal, and/or abnormal physical examination findings, vital signs measurements, ECGs, and clinical laboratory test results, related to treatment
Time frame: 1 year
Findings of the Brief Pain Inventory-Short Form (BPI-SF) during the Open-label Treatment Period
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Site 334
Huntsville, Alabama, United States
Site 328
Tucson, Arizona, United States
Site 332
Jacksonville, Florida, United States
Site 340
Miami Gardens, Florida, United States
Site 320
Plantation, Florida, United States
Site 302
Tampa, Florida, United States
Site 315
Tampa, Florida, United States
Site 310
Winter Haven, Florida, United States
Site 316
Dawsonville, Georgia, United States
Site 311
Marietta, Georgia, United States
...and 29 more locations